Blurbs

Analysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Armata Pharmaceuticals (ARMP) and Quotient (QTNT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sonnet BioTherapeutics Holdings (SONNResearch Report), Armata Pharmaceuticals (ARMPResearch Report) and Quotient (QTNTResearch Report) with bullish sentiments.

Sonnet BioTherapeutics Holdings (SONN)

BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings on February 8 and set a price target of $2.00. The company’s shares closed last Wednesday at $0.31, close to its 52-week low of $0.28.

According to TipRanks.com, Pohlman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -35.2% and a 0.0% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics, CytomX Therapeutics, and Gritstone Oncology.

Currently, the analyst consensus on Sonnet BioTherapeutics Holdings is a Strong Buy with an average price target of $2.17, a 588.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $2.00 price target.

See today’s best-performing stocks on TipRanks >>

Armata Pharmaceuticals (ARMP)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Armata Pharmaceuticals today and set a price target of $9.00. The company’s shares closed last Wednesday at $4.88.

According to TipRanks.com, Higgins is a 3-star analyst with an average return of 5.0% and a 31.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Viridian Therapeutics, and Astria Therapeutics.

Armata Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.

Quotient (QTNT)

BTIG analyst Sung Ji Nam maintained a Buy rating on Quotient yesterday and set a price target of $9.00. The company’s shares closed last Wednesday at $1.56, close to its 52-week low of $1.39.

According to TipRanks.com, Nam is a 4-star analyst with an average return of 7.0% and a 53.3% success rate. Nam covers the Healthcare sector, focusing on stocks such as Genetron Holdings, Alpha Teknova, and Olink Holding.

Quotient has an analyst consensus of Moderate Buy, with a price target consensus of $6.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SONN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos